Filgrastim associations with CAR T‐cell therapy

Little is known about the benefits and risks of myeloid growth factor administration after chimeric antigen receptor (CAR) T‐cell therapy for diffuse large B‐cell lymphoma (DLBCL). We present a retrospective analysis among 22 relapsed/refractory DLBCL patients who received CAR T‐cell therapy with ax...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaut, Daria, Tang, Kevin, Sim, Myung Shin, Duong, Tuyen, Young, Patricia, Sasine, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894177/
https://www.ncbi.nlm.nih.gov/pubmed/33091961
http://dx.doi.org/10.1002/ijc.33356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894177/
https://www.ncbi.nlm.nih.gov/pubmed/33091961
http://dx.doi.org/10.1002/ijc.33356

Ejemplares similares